Development and Clinical Evaluation of a CRISPR-Based Diagnostic for Rapid Group B Streptococcus Screening
Lingxiao Jiang
1, Weiqi Zeng
1, Wanting Wu
1, Yingying Deng, Fusheng He, Wenli Liang, Mingyao Huang, Hong Huang, Yongjun Li, Xiaorui Wang, Hang Su, Shilei Pan
, and Teng Xu
1
Author affiliations: Zhujiang Hospital, Southern Medical University, Guangzhou, China (L. Jiang, Y. Deng, W. Liang, M. Huang); Vision Medicals Center for Medical Research, Shenzhen, China (W. Zeng, W. Wu, H. Huang, Y. Li, X. Wang, H. Su, T. Xu); Key Laboratory of Animal Gene Editing and Animal Cloning in Yunnan Province and College of Veterinary Medicine, Yunnan Agricultural University, Kunming, China (W. Zeng, T. Xu); Zhujiang Hospital, Southern Medical University, Guangzhou (S. Pan)
Main Article
Figure 1
Figure 1. Schematic diagram of CRISPR-based diagnostic for rapid GBS screening. Swab samples are first eluted and followed by a rapid DNA extraction step where the bacterial cell walls are disrupted by a combination of chemical, physical, and heating effects. The extracted DNA is then subjected to the CRISPR/Cas reaction. The collateral nuclease activity of Cas proteins are activated upon specific binding of gRNA to the atoB gene. Fluorescent signal produced from cleaved probes is captured and indicates the presence of GBS. GBS, group B Streptococcus. gRNA, guide RNA; ssRNA, single-stranded RNA.
Main Article
Page created: July 14, 2021
Page updated: August 25, 2021
Page reviewed: August 25, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.